Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 19/20 | 0.52 |
| ▸ | TPO | P07202 | 18/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749175 | 1.00 | MPO (0.52) | MPOTPOCYP3A4KCNH2OPRM1 | |
| SCHEMBL30749375 | 0.90 | MPO (0.44) | MPOTPOCYP3A4KCNH2OPRM1 | |
| SCHEMBL27224085 | 0.82 | MPO (0.48) | MPOTPOCYP3A4KCNH2OPRM1 | |
| SCHEMBL1536641 | 0.81 | MPO (0.54) | MPOTPOCYP3A4KCNH2OPRM1 | |
| SCHEMBL30601263 | 0.79 | MPO (0.67) | MPOTPOCYP3A4KCNH2OPRM1 | |
| SCHEMBL1536595 | 0.79 | MPO (0.52) | MPOTPOCYP3A4KCNH2OPRM1 | |
| SCHEMBL30749377 | 0.78 | MPO (0.44) | MPOTPOCYP3A4KCNH2OPRM1 | |
| SCHEMBL30749170 | 0.77 | MPO (0.61) | MPOTPOCYP3A4KCNH2 | |
| SCHEMBL27224038 | 0.77 | MPO (0.61) | MPOTPOCYP3A4KCNH2 | |
| SCHEMBL30029669 | 0.75 | MPO (0.68) | MPOTPOCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038131-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-02-22 | — | — | WO | claimed |
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-05-23 | — | — | US | disclosed |
| WO-2024038131-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | MPO, XDH, EPX | MPO 1/4885TPO 10/4885CYP3A4 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.